Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TOPIC trial of topical imiquimod versus LLETZ for high-grade cervical intraepithelial neoplasia
NL-OMON41566Phase 3Active, not recruiting
- Sponsor
- Maastricht University Medical Center+
- Start
- Feb 2015
- Modality
- Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of imiquimod in cervical intraepithelial neoplasia (CIN) (2 arms), sponsored by Maastricht University Medical Center+. Primary endpoints: Regression of CIN2/3 after imiquimod and Adequate treatment of high-grade CIN by LLETZ. Started Feb 2015; status: active, not recruiting.
02
Drugs
imiquimod
03
Conditions
cervical intraepithelial neoplasia (CIN)
Beyond the preview
Go deeper on NL-OMON41566.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41566.